Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 192 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cell-culture Clear all
Completed Not applicable Interventional

Prevention of Malnutrition in Children With Sickle Cell Disease

NCT06397118
View directory record Official record
Conditions
Sickle Cell Disease, Malnutrition
Interventions
Maternal Nutrition Education, Standard Care
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 18 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 2, 2026, 1:57 PM EDT
Completed No phase listed Observational

C-Reactive Protein as a Predictor of Stem Cell Transplant Complications

NCT00179868
View directory record Official record
Conditions
Cancer, Leukemia, Stem Cell Transplantation
Interventions
C-Reactive Protein levels
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

NCT03722589
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 65 Years
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Early Phase 1 Interventional

The Role of IL5 in Epithelial Cell Integrity

NCT05895929
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)
Interventions
Mepolizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 1:57 PM EDT
Recruiting Not applicable Interventional

Collaborative Multi-level Obesity Intervention Engaging Communities Trial

NCT06835686
View directory record Official record
Conditions
Obesity
Interventions
Health Literacy and Culturally Tailored Materials, Community-Engaged Health Coaching and Navigation, Self-Monitoring and Remote Patient Monitoring of weight and physical activity, Community Asset Mapping (CAM), Primary Care Provider Training, Obesity Toolkit for Primary Care Providers
Behavioral · Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Avondale, Louisiana • Bastrop, Louisiana • Baton Rouge, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Dietary Oxysterols and β-Cell Function Among African Americans

NCT05072587
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Plant-based diet with no oxysterols, Standard ADA Diet (SADA)
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccine Feasibility Study in Children With Persistent Asthma

NCT02967393
View directory record Official record
Conditions
Asthmatic
Interventions
ccIIV4, IIV4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

NCT00813969
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Autologous mesenchymal stem cell transplantation
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants

NCT03694613
View directory record Official record
Conditions
Preterm Infant, Early-Onset Neonatal Sepsis, Umbilical Cord
Interventions
Placental/Umbilical Cord Blood sample
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 1 Day
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 2, 2026, 1:57 PM EDT
Terminated Phase 1 Interventional

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

NCT02781467
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
PNK-007, Cyclophosphamide, Fludarabine, Human recombinant Interleukin-2 (rhIL-2)
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 2, 2026, 1:57 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

NCT05400109
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Iowa City, Iowa • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00027807
View directory record Official record
Conditions
Breast Cancer
Interventions
Aldesleukin, Sargramostim, therapeutic autologous lymphocytes
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy

NCT04410731
View directory record Official record
Conditions
Facet-Mediated Low Back Pain
Interventions
Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)

NCT01451073
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
6
States / cities
Atlanta, Georgia • Chevy Chase, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945
View directory record Official record
Conditions
Prophylaxis of A/H3N2v Influenza
Interventions
Swine Influenza
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 92 Years
Enrollment
627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
11
States / cities
Redding, California • Sacramento, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 2, 2026, 1:57 PM EDT
Completed No phase listed Observational

Blood Volume Assessment in COVID-19 and Bacterial Sepsis

NCT04517695
View directory record Official record
Conditions
Covid19, Acute Respiratory Distress Syndrome, Bacterial Sepsis, Bacterial Infections
Interventions
BVA-100, Transpulmonary Thermodilution (TPTD), Sublingual Microcirculation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)

NCT01451190
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
9
States / cities
Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 2, 2026, 1:57 PM EDT
Recruiting No phase listed Observational

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

NCT02474160
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
2 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
140
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)

NCT01451125
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 2, 2026, 1:57 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

NCT04548583
View directory record Official record
Conditions
Crohn Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 2, 2026, 1:57 PM EDT